Skip to main content

Home/ Health and Fitness Club/ Group items tagged life-sciences-research

Rss Feed Group items tagged

pharmacybiz

MPs and peers urge Chancellor to support life sciences in upcoming Budget - 0 views

  •  
    The newly-formed All-Party Parliamentary Group (APPG) for Life Sciences has written to Chancellor of the Exchequer Rachel Jane Reeves, urging her to protect and promote the life sciences sector in the government's first Budget. The group, which includes MPs and peers, convened for its first meeting in Parliament on Tuesday (15 October) to discuss the steps the Labour government should take to ensure that the UK remains a global leader in life sciences research and commercialisation. Following the meeting, the group sent a letter to the Chancellor, expressing their support for the Labour Party's life sciences strategy, A Prescription for Growth, which was published before the general election. They urged the Chancellor to maintain government funding for life sciences research and manufacturing, as well as the tax reliefs that encourage investment, in the Budget set for 30 October. Kit Malthouse MP, chair of the APPG, emphasised the potential of the life sciences sector, saying, "The Life Sciences sector holds out an incredible promise that the UK can be at the forefront of humanity's battle with disease and at the same time build a 21st century knowledge-based economy.
pharmacybiz

UK Life Sciences : New Report 2024 Uncovers Challenges & Opportunities - 0 views

  •  
    "The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.
pharmacybiz

UK must swiftly fend off competition | Life sciences Vision - 0 views

  •  
    The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.
pharmacybiz

DHSC New NIHR RDN Transforming UK Research - 0 views

  •  
    The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and social care research in England. The network, which will start operating from next year, will play a critical and active role in implementing government policies. It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development. The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition. Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global leadership role.
pharmacybiz

Precision Medicine Launchpad Boosts NI's Life Sciences - 0 views

  •  
    The 'Life and Health Sciences Launchpad' has been introduced to focus on the precision medicine sector. It would help businesses and researchers to level up their impact on economic growth within the region. The launchpad has been funded by Innovate UK, part of UK Research and Innovation (UKRI). Kerry Curran, Director of GB & EU Trade in the Department for the Economy hailed the decision to support NI's "trailblazing" sector. She said: "Life and Health Science, including our highly innovative precision medicine cluster, is an area the Department is also prioritising through its 10X Economy Vision, and this Launchpad represents a further endorsement of the world-leading growth potential of precision medicine, and indeed life and health science, in Northern Ireland.
pharmacybiz

£260m to boost healthcare research and manufacturing : Govt - 0 views

  •  
    The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
pharmacybiz

£100M Investment to Launch 20 Research Hubs Across the UK | Pharmacy News - 0 views

  •  
    The government has announced a £100 million public-private investment to establish 20 new commercial research delivery centres (CRDCs) across the UK, aimed at increasing access to innovative treatments and clinical trials in underserved communities. These centres will be set up in all four nations: England, Scotland, Wales, and Northern Ireland, acting as regional hubs for pioneering clinical trials. These trials will span various conditions, including cancer, obesity, and infectious diseases like flu and respiratory syncytial virus (RSV). The hubs will facilitate the swift launch of commercial studies, ensuring that patients can access experimental treatments as soon as possible. Health Minister Baroness Gillian Merron hailed the investment as "a powerful vote of confidence in the UK's leading research and life sciences sector." She noted that the new hubs will shift research into smaller communities, allowing more people to access cutting-edge treatments faster.
pharmacybiz

ABPI Calls for Action in Labour's First 100 Days:UK Life Sciences Boom - 0 views

  •  
    The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office. Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA). Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay. Other measures the ABPI wants Labour to prioritise include: Rapidly passing outstanding UK clinical trials legislation to enhance the UK's attractiveness for inward investment, including into research within the NHS. Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.
pharmacybiz

£400M VPAG Programme: Revolutionizing UK's Clinical Trials & Health Sector Gr... - 0 views

  •  
    The UK government has announced the launch of a new joint public-private investment programme aimed at accelerating patient access to cutting-edge treatments, enhancing clinical trials, and bolstering the country's medicines manufacturing capabilities. Supported by up to £400 million of investment, the Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) Investment Programme is set to inject significant resources into the UK's health and life sciences sector over the next five years. Believed to be the world's first major public-private collaboration of this scale globally, the VPAG Investment Programme is designed to boost economic growth and the global competitiveness of the UK's life sciences sector. It aims to strengthen the NHS by supporting innovative research and creating 18 new clinical trial hubs to fast-track the development of new medicines for patients. The programme will also streamline processes to ensure the rapid transition of new treatments from labs to wards, providing patients with faster access to cutting-edge treatments. Health and Social Care Secretary Wes Streeting hailed this private investment as "a significant vote of confidence in the UK" highlighting that it will fast-track the next generation of treatments to NHS patients.
Bharatbookbureau MarketReport

#Agricultural #science #China - 0 views

  •  
    Includes latest collection of China Agricultural science research and test development industry companies with annual revenue above 5 million USD.
pharmacybiz

Boehringer Ingelheim 's Uday Bose is elected chair of EMG - 0 views

  •  
    Boehringer Ingelheim's UK & Ireland managing director Uday Bose has been elected chair of the European Medicines Group (EMG). Established in 2001, the EMG is a voice for UK operations of continental European headquartered research-based pharmaceutical companies and seeks to promote a dialogue between the UK Government, the NHS and wider stakeholders. "I am delighted to share the news that I have been elected chair," Bose wrote in a LinkedIn post, adding: "I look forward to working with the EMG to help support the ambition set out in the Life Sciences Vision for the UK to be a world leader in life sciences." Bose is a vastly experienced pharmaceutical industry leader who has had over 20 years' experience spanning general management, health economics, sales and marketing roles with national, regional and global accountability.
pharmacybiz

UK Government Statutory Scheme Consultation for Medicine - 0 views

  •  
    The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.
pharmacybiz

ABPI:Voluntary Scheme for Pricing, Access and Growth - 0 views

  •  
    The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.
pharmacybiz

UK could avoid 20,000 cancer deaths a year by 2040 with an ambitious plan, says charity - 0 views

  •  
    The UK is lagging behind comparable countries when it comes to cancer survival, Cancer Research UK (CRUK) has said, calling on all political parties to make cancer a top priority in their party manifestos. While cancer survival rates in the UK have doubled over the last 50 years, the charity warned that the hard-won progress is at risk of stalling, with NHS cancer services in "crisis" and around half a million cancer cases a year projected by 2040. The charity has published an ambitious cancer plan which, if adopted by the next UK government, could dramatically improve cancer outcomes and prevent 20,000 cancer deaths a year by 2040. Called "Longer Better Lives: A Manifesto for Cancer Research and Care", the plan has been developed with the insights of cancer patients and experts from across health, life sciences, government and academic sectors, it said.
pharmacybiz

Moderna joins ABPI aims to strengthen its footprint in UK - 0 views

  •  
    Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.
insightscare

Implementation of Bioengineering to build Human Liver - Insights care - 0 views

  •  
    Science and technology help for the better lifestyles. It has transformed human life more efficiently. We must agree with this as not even a single field is there where we don't use technology. But still, research is ongoing for finding some new technologies by using previously available knowledge and techniques.
  •  
    It may also be useful in case of organ absence. Also, we need to get the fully functional body tissue which is easy to transplant.
insightscare

Biotechnology Archives - Insights care - 0 views

  •  
    Science and technology help for the better lifestyles. It has transformed human life more efficiently. We must agree with this as not even a single field is there where we don't use technology. But still, research is ongoing for finding some new technologies by using previously available knowledge and techniques. If we think from the health point of view, is every person having better health? No, a lot of people are having various health problems. Some have serious diseases while some have dysfunction of the organs.
krishangikapoor

Power Gummies - Fostering Your Lifestyle, Cherishing Your Health - 0 views

  •  
    Power Gummies - "Health Powered By Happiness & Backed By Science". Power Gummies Coming Forward To Simplify Everyone's Good Health. Health is the foundation of life, and Nutrition is the key to it. Our lifestyles have led us to compromise our nutrition needs and its after-effects are showing in our deteriorating health. This situation sets Power Gummies® as a provider in the journey to nutrition, enabling tasty yet effective ways to be healthy, getting rid of the fear and complexities of existing pill solutions. For starters, we decided to create health products backed by scientific evidence that would be made from best-in-class vegan-based ingredients and fix the root causes of problems to give complete nutrition. Equally important for us, was to make products that are tasty and fit into our lifestyles. At Present, Power Gummies has 4 Product Variants - # Hair & Nails Vitamin Gummies - 1 Month & 2 Months Pack # The Beach Body Gummies - 1 Month & 2 Months Pack. The Products are designed in Rabbit Shaped Sweet & Delicious Gummies to cater an individual's Hairs, Nails, Skin, Bloating, Water Shedding related issues and much more. - Our Hair & Nail Vitamins are delicious and suitable for everyone. These Hair & Nail Vitamins are Best Source to Boost Your Hair Growth & Strengthen Your Nails. - Our Beach Body Gummies Vitamins are delicious and suitable for everyone. These Beach Body Gummies are Best Solution to the Problems of Bloating, Water Shedding, Acidity, Body Imbalancement and much more. These are lab tested for purity and scientifically backed on Biotin, Folic Acid, Vitamin C, Green Coffee Extract, L-Carnitine and many more Lifestyle Focused Nutrients. It's completely based upon the research published by the European Food & Safety Association. Today, Power Gummies® have spread happiness to over 100,000 lives, inspired more than 100 celebrities and every day, Power Gummies® is enabling 2000+ visitors to discover simple and tasty ways to g
AMVital Nutrition

Ginger Benefits Sexual Health in Males-Know the Science!| AMVital - 0 views

  •  
    When someone says erectile dysfunction, the first thing that you may think is of "Viagra" or similar drugs to revive your sex crusade. Even if established medics can assist, they induce side effects, which is why most men choose natural options. Besides, adverse effects of Viagra can result in back pain, memory issues, nausea, loss of hearing, and more. When shifting to natural remedies, you can improve your sexual version without giving the body a ridiculous amount of toxins and chemicals. Ginger, a root vegetable and one of the main ingredients in many traditional Asian dishes, has been used for centuries in conventional medications to treat various ailments. In recent years, ginger has received attention as an herbal remedy for sexual health problems such as erectile dysfunction (ED), premature ejaculation (PE), and infertility. It turns out that this ancient herb can be very effective at improving your sex life! How Does Ginger Benefits Male Sexually? Its potent medicinal combinations have made this natural treatment a focal point in investigations and comprehensive research over the years. Here is what makes ginger (zingiber officinale) a mighty sexual therapy. We've enclosed all the benefits it can suggest. But, nothing has gained more momentum than its impact on male sexual ability. 1. Ginger is an aphrodisiac and boosts sex drive. Ginger has been used as an aphrodisiac for centuries. An aphrodisiac is any food or medicine that stimulates sexual intuition, cajoles veneral craving, and boosts pleasure and performance. The spicy flavor of ginger can help increase your libido and has also been shown to improve erectile dysfunction and sexual performance in men. Aside from its role as an aphrodisiac, ginger is also a known sperm motility enhancer. In fact, according to clinical studies, just one gram of fresh ginger can improve sperm count by up to 35 percent! 2. It can improve sexual satisfaction. Ginger can also improve overall sexual satisfaction by
jim con

Now, cancer diagnosis in 15 minutes | eHEALTH Magazine - 0 views

  •  
    Diagnosis of life-threatening diseases such as cancer may become a matter of minutes as scientists have developed a new bio-sensor technology, which they claim provides results within 15 minutes. "The technology uses antibodies to detect biomarkers - molecules in the human body which are often a marker for disease - much faster than current testing methods," said co-researcher Paul Millner from the Faculty of Biological Sciences at the University of Leeds.
1 - 20 of 20
Showing 20 items per page